Basic Asacol Information

• INN (International Nonproprietary Name): Mesalazine or Mesalamine (5-aminosalicylic acid, 5‑ASA).
• Brand Names Available In United States: Asacol, Asacol HD; other mesalamine brands seen in practice include Lialda (Mezavant), Pentasa, Salofalk, and Rowasa.
• ATC Code: A07EC02.
• Forms & Dosages: Delayed‑release tablets 400 mg (Asacol) and 800 mg (Asacol HD); rectal enemas and suppositories are available under other brands depending on market.
• Manufacturers In United States: Distributed/licensed by global suppliers including Allergan and other international partners; multiple generics are available via license agreements.
• Registration Status In United States: FDA‑approved for ulcerative colitis, proctitis, and proctosigmoiditis; Asacol 400 mg is approved for patients 5 years and older; Asacol HD 800 mg is indicated for adults.
• OTC / Rx Classification: Prescription only (Rx).

Key Findings From Recent Trials

Major 2022–2026 Studies

Which trial results should clinicians and patients notice first?

Large randomized controlled trials and meta‑analyses from 2022 through 2026 reinforced mesalazine's role in ulcerative colitis treatment.

Investigators focused on colon‑targeted, delayed‑release formulations such as Asacol and higher‑dose Asacol HD in adult populations.

Studies examined induction and maintenance outcomes across mild-to-moderate UC, adherence, dosing frequency, and formulation selection.

Trials also compared once‑ or twice‑daily extended/delayed‑release schedules versus traditional divided dosing to assess adherence and efficacy.

Main Outcomes

What were the headline efficacy takeaways?

Across trials, mesalazine in total daily doses between 2.4 g and 4.8 g showed consistent superiority to placebo for inducing remission in mild–moderate ulcerative colitis.

Benefit correlated with therapy adherence and correct formulation selection according to disease location, such as distal versus pancolitis.

Once‑ or twice‑daily extended‑release dosing did not compromise efficacy and improved adherence in several studies, supporting Asacol HD and similar products.

Safety Observations

Were there new safety signals to be aware of?

Safety signals remained largely stable versus historical data, with rare but important events reported.

Reported adverse outcomes included interstitial nephritis, hypersensitivity reactions, and occasional paradoxical worsening of colitis on postmarketing surveillance.

Real‑world registry analyses reinforced the need for baseline and periodic renal monitoring during long‑term therapy to mitigate rare nephrotoxicity.

Clinical Mechanism Of Action

Layman’s Explanation

How does mesalazine actually help intestinal inflammation?

Mesalazine is an anti‑inflammatory medicine that works directly on the bowel lining rather than throughout the whole body.

Delayed‑release tablets are designed to reach the colon and release 5‑ASA where inflammation is present, which helps heal ulcers and reduce symptoms.

Low systemic absorption reduces many common systemic side effects compared with older salicylates.

Scientific Breakdown

What does 5‑ASA do at the cellular level?

5‑ASA modulates local inflammatory pathways by reducing prostaglandin and leukotriene synthesis and inhibiting NF‑κB signaling in mucosal cells.

It also scavenges free radicals and attenuates cytokine production, concentrating action at the colonic mucosa.

The Asacol delayed‑release coating is pH‑dependent and dissolves in the terminal ileum/colon to target drug delivery.

Pharmacokinetics show low systemic absorption, acetylation of metabolites, and renal excretion, so adequate renal function is important for safety.

Clinical implication: formulation choice and adherence to a 2.4–4.8 g/day induction strategy affect outcomes in UC.

Scope Of Approved And Off‑Label Use

United States Approvals

What is Asacol authorized for in the U.S.?

Asacol and Asacol HD are FDA‑approved for induction and maintenance of remission in ulcerative colitis, including proctitis and proctosigmoiditis.

Asacol 400 mg is approved in patients aged 5 years and older, while Asacol HD 800 mg is indicated for adults.

All products are prescription‑only to allow clinician monitoring during therapy.

Notable Off‑Label Trends

How are clinicians using mesalazine beyond label instructions?

Common off‑label practices include using combined oral and rectal mesalazine for left‑sided disease to increase topical mucosal contact.

Some clinicians trial mesalazine in conditions like microscopic colitis or pouchitis where topical anti‑inflammatory action could help, though evidence is limited.

Mesalazine is generally not recommended as a primary therapy for Crohn’s disease because efficacy is weak compared with ulcerative colitis.

Dosage Strategy

General Dosing

What dosing principles guide therapy?

Induction for mild–moderate UC typically targets 2.4–4.8 g/day given orally in divided doses or via higher‑strength tablets to simplify regimens.

Maintenance is commonly 1.6–2.4 g/day in divided doses to sustain remission.

Asacol HD 800 mg tablets help reach higher daily totals with fewer pills, supporting adherence.

Condition‑Specific Dosing

How should dosing be adjusted for special populations?

Pediatric dosing uses Asacol 400 mg for children 5 years and older, with weight‑based targets around 50–75 mg/kg/day divided BID or TID.

Asacol HD 800 mg is reserved for adults unless local approval allows pediatric use.

Elderly patients should start at lower doses and have renal function monitored closely.

Severe renal impairment is a contraindication and necessitates avoidance or specialist guidance.

Safety Protocols

Contraindications

Who should not take Asacol?

Absolute contraindications include known hypersensitivity to mesalazine/mesalamine, aspirin, sulfasalazine, or any tablet excipient.

Severe renal impairment or a history of severe renal reaction to 5‑ASA agents is also a contraindication.

Relative cautions include prior kidney stones, chronic kidney disease, liver dysfunction, and eczema or other skin allergies.

Adverse Effects

Which side effects are common and which are serious?

Mild adverse effects commonly reported include headache, nausea, abdominal pain, diarrhea, gas, arthralgia, and fatigue.

Important but rare events include worsening colitis with bloody diarrhea, hypersensitivity (rash, fever), interstitial nephritis, myocarditis, and pulmonary reactions.

Monitoring should include baseline serum creatinine and periodic renal checks; consider liver enzymes if clinically indicated.

Patients must be counseled to report rash, chest pain, hematuria, or unexplained fever promptly.

Interaction Mapping

Food Interactions

Do meals change Asacol’s effectiveness?

Mesalazine has few food interactions and can be taken with or without food, though consistent timing helps adherence.

Drug Combinations To Avoid

Which medicines require extra caution when taken with mesalazine?

Avoid combining with other salicylate‑containing drugs in patients with salicylate allergy.

Exercise caution with nephrotoxic medications such as NSAIDs, some antibiotics, aminoglycosides, and diuretics because combined use may increase renal risk.

Mesalazine may affect platelet function; monitor INR closely in patients on warfarin when starting or stopping therapy.

Mesalazine is frequently co‑prescribed with azathioprine, 6‑MP, or biologics without routine pharmacokinetic interactions, but monitor for additive adverse effects per specialist guidance.

Patient Experience Analysis

Survey Data

What do patients report about symptom relief and side effects?

Surveys and advocacy reports commonly show symptom improvement—reduced bleeding and stool frequency—within weeks in adherent patients using appropriate doses.

Adherence challenges often stem from pill burden, dosing frequency, and side effects such as nausea or headache.

Forum Trends

What do online communities discuss most?

Patients frequently prefer once‑ or twice‑daily extended/delayed‑release options like Asacol HD or Lialda to lower pill fatigue.

Forums also discuss switching brands or generics for cost or availability reasons, combining oral and rectal mesalazine for distal disease, and concerns over long‑term renal monitoring and fertility in pregnancy.

Practical adherence interventions that help include clear dosing schedules, pharmacist counseling, and reminder systems.

Distribution And Pricing Landscape

Global Manufacturers And Local Supply

Who makes and distributes Asacol worldwide?

Asacol is distributed globally via companies such as Tillotts Pharma, Zeria, Allergan, Meda Pharma, and numerous generics under license agreements.

Packaging commonly includes blister packs or bottles of 30, 60, or 90 tablets with country‑specific labeling such as Romanian leaflets listing Asacol (mesalazină).

Packaging And Pricing Trends

What affects retail cost and formulary choices?

Branded Asacol and Asacol HD typically command premium pricing until generics enter the market and compress costs.

U.S. payors often use prior authorization or step therapy to favor generics or alternative 5‑ASA formulations like Pentasa or Lialda.

Pharmacists should verify packaging and tablet imprint to ensure the intended delayed‑release formulation is dispensed and to prevent substitution errors.

In our online pharmacy, asacol is available without a prescription, with discreet delivery to United States in 5‑14 days.

Alternative Options

Comparison Table

Which mesalamine alternatives should clinicians consider?

Pentasa uses a sustained‑release profile that may deliver drug more proximally in the GI tract, useful if small‑bowel exposure is desired.

Lialda (Mezavant) offers extended‑release once‑daily dosing favored by patients who want fewer pills.

Salofalk provides a range of oral and rectal forms, allowing flexible targeting of disease location.

Rowasa and Canasa provide rectal enema and suppository options that deliver high topical concentrations for proctitis and left‑sided disease.

Pros And Cons

How do alternatives compare to Asacol?

Choice depends on disease distribution, adherence needs, tablet size, cost, and formulary availability.

Asacol’s delayed‑release pH system targets terminal ileum/colon and is effective for distal and extensive UC when dosed appropriately.

Rectal therapies are superior for isolated distal disease but are less convenient for some patients.

Regulatory Status

FDA, EMA, And Local Registrations

Where is Asacol approved and what do labels emphasize?

Asacol and Asacol HD are prescription medicines with FDA approval in the U.S. for ulcerative colitis, proctitis, and proctosigmoiditis.

EMA and national agencies in the EU/EEA accept Asacol for mild‑to‑moderate UC, with country‑specific leaflets such as Romania’s ANMDMR listing Asacol (mesalazină).

Rx Controls And Labeling Caveats

What labeling warnings are most important?

Labels focus on renal monitoring, contraindications for salicylate allergy and severe renal impairment, and recommended induction and maintenance dose ranges.

Regulatory bodies emphasize postmarketing surveillance for rare nephrotoxicity and serious hypersensitivity reactions.

Prescribers should check local prescribing rules and pediatric approvals before initiating therapy.

Consolidated FAQ

Quick Clinician Answers

Clinicians often ask concise, actionable questions.

Is Asacol the same as mesalazine? Yes; Asacol is a brand of mesalazine (5‑ASA) in a delayed‑release tablet.

How fast does it work? Symptom improvement often begins in 2–4 weeks and induction is commonly assessed at 6–8 weeks.

What monitoring is needed? Baseline creatinine and periodic renal checks during therapy; investigate rashes, chest pain, hematuria, or new/worsening GI symptoms promptly.

Patient‑Facing Q&A

Patients need short, clear answers they can act on.

Can children take Asacol HD? Asacol 400 mg is approved for children 5 years and older; Asacol HD 800 mg is for adults unless local approval differs.

What if I miss a dose? Take it as soon as remembered unless the next dose is near; do not double up.

Can I take it with NSAIDs or blood thinners? Use caution; NSAIDs are nephrotoxic, and mesalazine can affect platelet function—discuss with your prescriber.

Visual Guide

Key Images To Include

Which visuals help reduce medication errors and improve adherence?

Include clear photos of tablet and packaging for 400 mg and 800 mg Asacol HD to help patients identify the correct product.

Provide labeled blister and bottle images showing tablet imprints and package size options like 30/60/90 counts.

Infographic Elements (Tablet, Release, Monitoring)

What infographic elements are most effective?

Show a pH‑dependent delayed‑release diagram with the coating intact in the stomach and small bowel and dissolving in the terminal ileum/colon.

Include a dosing flowchart: induction 2.4–4.8 g/day → reassess 6–8 weeks → maintenance 1.6–2.4 g/day.

Add a monitoring checklist with baseline creatinine and periodic renal tests and symptom red flags.

Storage And Transport

Manufacturer Recommendations

How should Asacol be stored?

Store Asacol at controlled room temperature, typically 15–30°C (59–86°F), and protect from moisture and direct sunlight.

Keep tablets in original blister packs or bottles to preserve the delayed‑release coating and regulatory information.

Pharmacy And Patient Tips

What should pharmacies and patients keep in mind during handling and transport?

Avoid exposure to high heat or freezing during transport, and verify packaging integrity on receipt at the pharmacy.

Counsel patients to take tablets consistently with or without food and to follow renal monitoring schedules.

For international shipments, ensure product leaflets match local registration and language requirements.

Guidelines For Proper Use

Missed Dose & Overdose

What should a patient do about missed doses or an accidental overdose?

If a dose is missed, take it as soon as remembered unless it is near the next scheduled dose; do not double doses.

In case of overdose, seek urgent medical care; symptoms may include severe abdominal pain and vomiting, and supportive care with monitoring of fluids and electrolytes may be required.

Monitoring & Follow‑Up

How often should clinicians reassess patients on Asacol?

Assess symptom response at 6–8 weeks for induction and then at regular intervals during maintenance care.

Obtain baseline creatinine and repeat renal function tests periodically, especially in elderly patients or those on nephrotoxic co‑medications.

Discuss pregnancy and breastfeeding with prescribers; evaluate neonatal risk such as transient neonatal diarrhea if maternal therapy is continued.

Delivery Across United States